Search details
1.
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
Br J Cancer
; 128(5): 877-885, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36482190
2.
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes.
Cancer Chemother Pharmacol
; 92(6): 501-510, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37725113
3.
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.
Cancer Treat Rev
; 104: 102357, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-35184001
4.
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
Cancer Treat Rev
; 100: 102262, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34418781
5.
Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.
Front Oncol
; 9: 759, 2019.
Article
in English
| MEDLINE | ID: mdl-31456944
6.
Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.
Clin Genitourin Cancer
; 17(5): e903-e908, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31375351
Results
1 -
6
de 6
1
Next >
>>